ArticleHistopathology2025
Stroma areactive invasion front areas (SARIFA) in 1,298 pT3/pT4 colorectal cancers: A strong prognostic parameter complementing established morphological criteria.
Article in Histopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Association of SARIFA with Poor Prognosis and Aggressive Tumor Phenotypes in Cancers: A Meta-Analysis.Journal of clinical medicine · 2026Review
- Energy Balance-Related Factors and Direct Tumor-Adipocyte Contact in Colorectal Cancer: Etiologic Insights from the Population-Based Netherlands Cohort Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Distinct NK cell dynamics in SARIFA positive colorectal cancer patients indicate persistent patient-intrinsic immune signatures after tumor resection.Scientific reports · 2026Article
- Deep learning-based H&E-derived risk scores in colorectal cancer: associations with tumour morphology, biology, and predicted drug response.The Journal of pathology · 2026Article
- [SARIFA: Literature review and expert opinion on the new morphological biomarker].Pathologie (Heidelberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
aimsColorectal carcinoma (CRC) is one of the most common cancers worldwide and is associated with significant morbidity and mortality. Histopathology plays a crucial role in the diagnosis, prognostication and treatment planning of CRC. In addition to well-established morphological parameters such as tumour budding, grade and histopathological subtypes, the interaction between tumour cells and adipose tissue has gained increasing attention. METHODS AND
resultsThe frequency of direct proximity between cancer cells and adipocytes, termed Stroma Areactive Invasion Front Areas (SARIFA), was assessed in a multicentre cohort of 1,298 patients with pT3/pT4 CRC. The prognostic impact of SARIFA was evaluated, with a particular focus on its relationship with established histopathological parameters. SARIFA was associated with adverse clinicopathological features and served as an indicator of poor prognosis across all survival metrics in the overall cohort (disease-specific survival [DSS]; P < 0.001). This prognostic value remained significant across all pTNM stages (e.g. DSS in pT3, pN0, pN1/2, pM0 CRC; P < 0.001, respectively) and identified additional adverse prognostic subgroups within tumour budding and grade categories (DSS, P < 0.001, respectively) and within histopathological subtypes. In multivariable analyses, including pTNM stage and the aforementioned histopathological parameters, SARIFA remained a highly significant prognostic factor (DSS P < 0.001, hazard ratio: 1.73). DISCUSSION: Our study confirms the high prognostic relevance of SARIFA across key clinicopathological subgroups of CRC and highlights its value as a meaningful complement to established morphological parameters. Given its ability to provide additional prognostic insights, our findings advocate for its inclusion in pathology reports to improve risk assessment and clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.